Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer OTC Drugs

BASF acetaminophen acquisition

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

BASF Pharma buying bulk acetaminophen production business from Dallas-based Celanese, including the latter company's manufacturing plant in Bishop, Tex. "This acquisition is yet another step by BASF Pharma toward achieving its strategic goal to become a leader in the supply of bulk analgesics," the company says, calling itself a "market leader in the ibuprofen, pseudoephedrine and caffeine businesses." BASF Pharma also makes bulk ephedrine and theophylline. Celanese is the commodity chemicals and acetate products division of Hoechst

You may also be interested in...



Rhodia To Bolster Bulk Acetaminophen Business With BASF Asset Purchase

French specialty chemicals firm Rhodia has purchased BASF's acetaminophen business as part of a strategy to reinforce its bulk analgesic operations, the company announced Nov. 5

Rhodia To Bolster Bulk Acetaminophen Business With BASF Asset Purchase

French specialty chemicals firm Rhodia has purchased BASF's acetaminophen business as part of a strategy to reinforce its bulk analgesic operations, the company announced Nov. 5

Rhodia To Bolster Bulk Acetaminophen Business With BASF Asset Purchase

French specialty chemicals firm Rhodia has purchased BASF's acetaminophen business as part of a strategy to reinforce its bulk analgesic operations, the company announced Nov. 5

Table

View full table

Topics

Tags:
Consumer OTC Drugs
Latest Headlines

China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116

Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length

German HTA Queries Polivy Benefits Amid Lack Of Evidence

See All
UsernamePublicRestriction

Register

PS088886

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By